Key statistics
On Friday, argenx SE (0QW0:LSE) closed at 493.15, 17.39% above the 52 week low of 420.10 set on Jul 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 496.60 |
---|---|
High | 493.15 |
Low | 493.15 |
Bid | 467.10 |
Offer | 516.20 |
Previous close | 492.40 |
Average volume | 9.92k |
---|---|
Shares outstanding | 61.20m |
Free float | 61.11m |
P/E (TTM) | 35.50 |
Market cap | 30.14bn EUR |
EPS (TTM) | 13.87 EUR |
Data delayed at least 20 minutes, as of Jul 18 2025 17:33 BST.
More ▼
Announcements
- argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
- argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
- argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
- argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
- argenx Announces Results of Annual General Meeting of Shareholders
- argenx Reports First Quarter 2025 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2025 Health Care Conference
- argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
- argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- argenx Announces Annual General Meeting of Shareholders on May 27, 2025
More ▼